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Available online 10 September 2016Estrogendeﬁciency is one of themajor causes of osteoporosis in postmenopausalwomen. Drynariae Rhizoma is a
widely used traditional Chinese medicine for the treatment of bone diseases. In this study, we investigated the
therapeutic effects of the total Drynariae Rhizoma ﬂavonoids (DRTF) on estrogen deﬁciency-induced bone loss
using an ovariectomized rat model and osteoblast-likeMC3T3-E1 cells. Our results indicated that DRTF produced
osteo-protective effects on the ovariectomized rats in terms of bone loss reduction, including decreased levels of
bone turnover markers, enhanced biomechanical femur strength and trabecular bone microarchitecture deteri-
oration prevention. In vitro experiments revealed that the actions of DRTF on regulating osteoblastic activities
were mediated by the estrogen receptor (ER) dependent pathway. Our data also demonstrated that DRTF
inhibited osteoclastogenesis via up-regulating osteoprotegrin (OPG), as well as down-regulating receptor activa-
tor of NF–κB ligand (RANKL) expression. In conclusion, this study indicated that DRTF treatment effectively sup-
pressed bone mass loss in an ovariectomized rat model, and in vitro evidence suggested that the effects were
exerted through actions on both osteoblasts and osteoclasts.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Drynariae Rhizoma1. Introduction
As the population ages, osteoporosis is becoming an increasingly
common disease. It is a major public health problem worldwide,
which requires effective medicine or approaches for prevention and
treatment (Banu et al., 2012). In particular, postmenopausal women
are at high risk of developing osteoporosis due to signiﬁcant alterations
in bonemetabolism associatedwith estrogen deﬁciency. The rapid bone
loss and high bone fragility during menopause lead to increasing inci-
dence rates of spine, hip and wrist fractures among postmenopausal
women (Al-Anazi et al., 2011; Sundeep, 2010).Estrogen replacement
therapy (ERT), which is themajor therapy for the prevention and treat-
ment of postmenopausal osteoporosis (PMOP) (Kyvernitakis et al.,
2015), was reported to be associated with an increased risk of breast
cancer, ovarian cancer, endometrial cancer and cardiovascular disease
development in postmenopausal women (Davison and Davis, 2003;
Foidart et al., 2007;Morch et al., 2009). Thus, development of affordable
and alternative approaches with minimal side effects for PMOP has
attracted a great deal of attention. This is particularly important for
aging populations in developing countries, in which the majority of. This is an open access article underpatients cannot afford the long-term use of high-cost medications. Re-
cently, dietary phytoestrogens have been shown to be a rich source of
plant-derived natural compounds and have been identiﬁed as safe and
effective candidate drugs with estrogenic properties in the treatment
of PMOP (Cassidy, 2003). Plenty of Chinese herbs that are traditionally
used for the treatment of bone diseases exert estrogen-like activities
on bone (Chen et al., 2011b; Zhang et al., 2010; Zhang et al., 2011)
andmight serve as a potential source of phytoestrogens for themanage-
ment of PMOP. These phytoestrogens include soya isoﬂavones (Zhang
et al., 2008; Zhang et al., 2009), lignans (Lampe, 2003), and ﬂavonoids
(Mok et al., 2010; Pang et al., 2010). Previous reports showed that
phytoestrogens attenuated bone loss associated with estrogen deﬁcien-
cy in both animal and human studies (Dixon, 2004).
Drynariae Rhizoma is the dried rhizome of perennial pteridophyte
Drynaria fortunei (Kunze) J. Sm. (Polypodiaceae). As a traditional Chi-
nese medicine, Drynariae Rhizoma is widely used for the treatment of
bone fractures or related diseases in Asian countries. In Chinese it is
named “Gusuibu” which means bone fractures healer (Huang et al.,
2014). The crude extract of Drynariae Rhizoma has been shown to pro-
mote osteoblast differentiation and mineralization in preosteoblastic
cells (Chen et al., 2011a) aswell as inhibit bone resorption inmouse os-
teoclasts in vitro (Jeong et al., 2003). In vivo research indicated that ad-
ministration of Drynariae Rhizoma crude extract to 8-week-old BALB/cthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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becular number by 10%. Additionally, Rhizoma Drynariae extracts can
also induce bone formation on the margins of defects created in New
Zealand white rabbits parietal bone (Wong et al., 2007).
The major bioactive constituents of Drynariae Rhizoma are ﬂavo-
noids, which have attracted considerable attention for their potential
roles in osteoporosis prevention and stimulatory activity on osteoblasts
differentiation (Wang et al., 2008). Naringin and neoeriocitrin are the
two major ﬂavonoid compounds with the highest concentrations in
Drynariae Rhizoma (Xu et al., 2016). It has been reported that naringin
exerts positive effects in bone via ER-dependent pathways (Lu et al.,
2006). Although these results are encouraging, whether DRTF exerts es-
trogen-like activities, has beneﬁcial effects in estrogen deﬁciency-in-
duced osteoporotic rats and the possible molecular mechanisms for
this remain to be explained. To address these questions, the anti-osteo-
porotic effects and the potential mechanisms of DRTF on osteoporosis
prevention and treatment were systematically investigated and 17-β-
estradiol (E2) was used as a positive control drug in the present study.
2. Materials and methods
2.1. Reagents
Total Drynariae Rhizoma ﬂavonoids (DRTF) were purchased from
Beijing Qihuang Pharmaceutical Manufacturing Co., Ltd. (NationalMed-
icine Permit No. Z20030007, number of production: 04080081, the con-
tent of DRTF ≥ 80%). Alpha-Minimum Essential Medium (α-MEM) was
purchased from Life Technologies (USA). Fetal bovine serum (FBS)
was obtained from ExCell Biology, Inc. (China). Ascorbic acid (AA), β–
glycerophosphate (β-GP) and Alizarin Red S were purchased from
Sigma-Aldrich (USA). Rat turnover markers ELISA kits were purchased
from Biocalvin (Suzhou, China). RIPA lysis solution and a BCA protein
assay kit were purchased from HEART biological technology Co., Ltd.
(China). The RNAprep Pure Tissue Kit was purchased from TianGen Bio-
tech Co., Ltd. (China). The PrimeScript™ RT reagent kit (Perfect Real
Time) and SYBR Premix Ex Taq™ reagentwere purchased from TAKARA
Biotechnology (China). Anti-OPG antibody was purchased abcam
(USA). Anti-ERα and anti-ERβ antibodies were purchased from R&D
Systems (USA). Anti-GAPDH (Glyceraldehyde-3-phosphate dehydroge-
nase) antibodywas obtained fromProteintech (China). Anti-RANKL and
Horseradish peroxidase (HRP) conjugated antibodies were purchased
from Ruiying bio (China).
2.2. Analysis the major constituents of DRTF
The naringin and neoeriocitrion in DRTFwere identiﬁed by high per-
formance liquid chromatography (HPLC), (LC-2010C, Shimadzu, Japan)
and mass spectrometry (MS), (Esquire 6000, Bruker, Germany). The
HPLC method was as follows: the reference solution was prepared
by dissolving 1.69 mg naringin and 1.58 mg neoeriocitrin in 5 ml of
methanol in a volumetric ﬂask, separately. The DRTF samples were
also dissolved in methanol and prepared as with the test solution. A
10 μl solution was subjected to HPLC and analyzed with a UV detector
(SPD-M20A, Shimadzu, Japan) at 283 nm. The separating conditions
were as follows: chromatographic column, MERCK C18
(4.6 × 250 mm, ID, 5 μm); column temperature, 30 °C; mobile phase
was methanol (A): 0.2% acetic acid water (B). The gradient elution
was as follows: 0–14 min, 30%–35% A; 14–22 min, 35%–50% A; 22–
26 min, 50%–35% A; 26–35 min, and 35%–35% A, with a ﬂow rate of
1.0 ml/min. The relative percentages of naringin and neoeriocitrin in
the DRTF were calculated from area normalization of total chromato-
grams by a computerized integrator. The naringin and neoeriocitrin
structures are shown in Fig. 1A and B. The MS identiﬁcation conditions
are as follows: the ion source was ESI, the atomization pressure was
35 psi, the dry gas ﬂow rate was 11 ml/min, the drying temperaturewas 350 °C, the mass range of mass spectrometry were 100–
1000 amu, and the ion mode was negative.
2.3. Animals and treatments
Three-month-old Sprague–Dawley speciﬁc pathogen-free female
rats (SIPPR-BK Experimental Animal Ltd., body weight, 250 ± 20 g)
were supplied by the Animal Center of the Fourth Military Medical Uni-
versity (Xi'an, China). The rats were housed with a 12/12 h light/dark
cycle at 22 °C. During the experimental period, the ratsweremaintained
on standard rodent chow and ﬁltered water, which was available ad
libitum. The acclimatized rats underwent either bilateral laparotomy
(Sham, n= 8) or bilateral ovariectomy (OVX, n= 40). One week after
recovering from surgery, the ovariectomized rats were randomly divid-
ed into ﬁve groups: OVX with vehicle (OVX, n = 8); OVX with E2 (E2,
n = 8, 25 μg/kg body weight/day) or OVX with graded doses of DRTF
(DRTF25, n = 8, 25 mg/kg body weight/day; DRTF75, n = 8, 75 mg/
kg body weight/day and DRTF225, n = 8, 225 mg/kg body weight/
day). Vehicle, E2 and DRTF were all administered orally through a cus-
tom-made stomach tube, which lasted for 12 weeks. The body weights
of the rats were recorded every two weeks to assess changes. The bone
mineral content (BMC) and bone mineral density (BMD) were mea-
sured by dual-energy X-ray absorptiometry (DEXA) two days before
the animals were euthanized. Urine samples were collected from the
rats that were housed individually for 24 h in metabolic cages without
providing food 1 day before euthanasia. Then, the samples were acidi-
ﬁedwith 2 ml 1mol/l HCl. After the rats were anesthetized with pento-
barbital sodium, a laparotomy was performed and blood samples were
collected by abdominal aorta puncture from each anesthetized rat.
Serum was then prepared by centrifugation (3000g for 10 min at 4 °
C). Urine and serum samples were stored in aliquots at−80 °C for bio-
chemical determinations. The uterus, heart, liver, spleen, lung, kidney,
brain, and thymus were removed and weighed immediately. The uteri
were put into 10% formalin solution for preservation. After 72 h of ﬁxa-
tion, the uteri were parafﬁn embedded, sectioned and dyedwith hema-
toxylin/eosin (HE). Femurs were dissected and placed in physiological
saline and stored at−80 °C for bone biomechanical quality measure-
ment with a three-point bending test. Additionally, trabecular bone
microarchitecture was evaluated by micro-computed tomography
(micro CT). All animals were treated in compliance with the principles
and procedures contained in themost recent publication of theNational
Institutes of Health guide for the care and use of laboratory animals
(NIH, 2011).
2.4. Assay for serum and urine chemistry
Serum calcium (S-Ca), serum phosphorus (S-P) and alkaline phos-
phatase (ALP) concentrations were measured by standard colorimetric
methods using commercial kits (Nanjing Jiancheng Bioengineering
Ltd., China) and analyzed with a multi-functional microplate spectro-
photometer (SpectraMax M4, Molecular Devices, USA) (Zhai et al.,
2014). Urine calcium (U-Ca), Urine phosphorus (U-P) and creatinine
(Cr) concentrations were analyzed by the same method used for the
serum samples. Urinary deoxypyridinoline (DPD), serum C-terminal
telopeptide of type I collagen (CTX-Ι), osteocalcin (OC), propeptide of
type I procollagen (PICP) and tartrate-resistant acid phosphatase
(TRAP) levels were determined using rat ELISA kits (Biocalvin, Suzhou,
China). Urinary Ca, P and DPD excretion were all expressed as the
ratio to Cr concentration (Ca/Cr, P/Cr, DPD/Cr).
2.5. DEXA analysis
The BMD and BMC fromwhole animals were measured with a dual-
energy X-ray absorptiometer (Lunar Prodigy Advance DEXA, GE
healthcare, Madison, WI, USA) using the small laboratory animal scan
mode (Pastoureau et al., 1995). The BMD and BMC values from the
Fig. 1. The structures of naringin (A) and neoeriocitrin (B); theHPLC chromatograms of the reference substances (C) and DRTF (D). Peak 1 is neoeriocitrion, peak 2 is naringin; the primary
mass spectrograms of naringin (E) and neoeriocitrion (F).
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ware (enCORE™ 2006, GE Healthcare, Madison, WI, USA).
2.6. Three-point bending test
Prior to mechanical testing, the left femurs were removed from the
freezer, submerged in physiological saline solution to thaw slowly,
and held at room temperature on the day of testing. Then, each speci-
men was placed in a material testing machine on two supports that
were separated by a distance of 20mmand loadwas applied to themid-
dle of the diaphysis, thus creating a three-point bending test. The bio-
mechanical quality of the left femoral diaphysis was determined using
AGS-10KNG material testing machine (SHIMADU, Japan) at a speed of
2 mm/min until fracture occurred. The central loading point was
displaced, and the load and displacement values were recorded until
the specimen was broken. From the load-deformation curve, the maxi-
mum load (ultimate strength, Fmax), energy absorption (area under the
curve, Wabs) and stiffness (slope of the linear region of the curve
representing elastic deformation), maximum stress (Fmax/cross-sectional area, σmax) and Young's modulus values (maximum slope of
the stress-strain curve, E) were obtained.
2.7. Micro CT analysis
The distal metaphysis in the right femur of each rat was scanned
with Inveon micro CT (Siemens, Germany). The graphic image resolu-
tion was 1024 × 1024. Three-dimensional (3D) image data were ac-
quired with a voxel size of 20 × 20 μm in all spatial directions with a
micro CT evaluation program (V5.0A) (Laib et al., 2000). The volumes
of interest (VOI), which were located 1 mm from the metaphyseal line
to 2mm(the 100 continuous slices) below it,were chosen for data anal-
ysis. The 3D segmented images were directly used to quantify
microarchitecture with the Micro-View program (Siemens, Germany)
and a multiple Intel® processors-based micro CT workstation. Morpho-
logical measurements were performed and the following 3D parame-
ters were obtained by analyzing the VOIs for the trabecular bone: (1)
the bone volume/tissue volume (BV/TV), (2) trabecular number
(Tb.N), (3) trabecular thickness (Tb.Th), (4) trabecular separation
Table 1
The primer sequences of real time RT-PCR.
Gene GeneBank no. Primer sequences Annealing temperature (°C) Product length (bp)
OPG NM_008764.3 Forward: 5′-CCAAAGTGAATGCCGAGAGT-3′ 57 154
Reverse: 5′-ACGCTGCTTTCACAGAGGTC-3′ 57
Rankl NM_011613.3 Forward: 5′-CTCACCATCAATGCTGCCAG-3′ 58 162
Reverse: 5′-GCAAATGTTGGCGTACAGGT-3′ 58
ERα NM_001302533.1 Forward: 5′-TGAAAGGCGGCATACGGAAA-3′ 60 105
Reverse: 5′-TGTCTCCTGAAGCACCCATT-3′ 60
ERβ NM_010157.3 Forward: 5′-TAGAGAGCCGTCACGAATAC-3′ 58 161
Reverse: 5′-GGCTAAAGGAGAGAGGTGTC-3′ 58
GAPDH NM_008084.2 Forward: 5′-AGGGCATCTTGGGCTACACT-3′ 58 161
Reverse: 5′-CACCCTGTTGCTGTAGCCGT-3′ 58
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ness (Cb.Th) (Marinozzi et al., 2013).
2.8. Cell culture
MC3T3-E1 cells were cultured in α-MEM medium supplemented
with 10% FBS, 2.2 g/l sodium bicarbonate, 100 mg/ml streptomycin
and100 Units/ml penicillin, in a humidiﬁed 37 °C, 5% CO2 incubator.
For cell differentiation experiments, conﬂuent cells were cultured with
osteogenic medium that contained α-MEM supplemented with 10%
FBS, 100 mg/ml streptomycin, 100 units/ml penicillin, 50 mg/ml ascor-
bic acid and10 mM β-glycerophosphate (β-GP) and the medium was
changed every 2 or 3 days.
2.9. Cell proliferation assay
Cell proliferation was determined with an MTT assay. MC3T3-E1
cells were seeded at a density of 2 × 103 cells/well in 96-well plates
full of medium containing DRTF of various concentrations (0.1, 0.5,
2.5, 12.5, 62.5, or 312.5 μg/ml). After 24 and 48 h treatments, 20 μl of
MTT solution (0.5 mg/ml) was then added into each well and the mix-
ture was incubated for 4 h at 37 °C. Culture mediumwas then replaced
with an equal volume of DMSO to dissolve the formazan crystals. After
shaking at room temperature for 10 min, absorbance was measured at
570 nm with an Inﬁnite M200 multifunctional microplate reader
(Tecan, Austria). All experiments were performed in duplicate and re-
peated independently thrice.
2.10. Alkaline phosphatase activity
MC3T3-E1 cells were seeded at a density of 2 × 104 cells/well in 24-
well plates with osteogenic medium in the presence or absence of DRTF
(0.1, 0.5, 2.5, 12.5, 62.5, or 312.5 μg/ml). After 3 days, 6 days, 9 days and
12 days of treatment, cells were gently washed twice with PBS. Then,
the cells were lysed with 0.2% Triton X-100 and the lysate was centri-
fuged at 15,000g for 5 min. The supernatant was collected for alkaline
phosphatase (ALP) activity and protein concentration measurements
with an ALP activity assay kit and a BCA-protein assay kit, respectively
(Ehrlich et al., 2005; Yang et al., 2005).
2.11. Mineralized nodule measurement
Mineralization in MC3T3-E1 cells was determined by staining with
Alizarin Red-S. Alizarin Red-S binds selectively to calcium and stains it
dark red. Cells (2.5 × 104 cells/well) were seeded in 24-well plates
and cultured with osteogenic medium with or without DRTF (12.5 μg/
ml) during this period. Themediumwas changed every 2 days. After in-
cubation for 12 days, the cellswerewashedwith phosphate buffered sa-
line (PBS, pH 7.4), ﬁxed with 10% buffered formaldehyde for 15 min,
rinsed with PBS and stained with 0.5% Alizarin Red S (pH 4.2) for
15 min at room temperature. After staining, the cells were washed
with distilled water on a shaking platform for 5 min, 5 times. Imagesof the mineralized nodules were photographed using a microscope
(TS100, Nikon, Japan). Image J software (National Institutes of Health,
NIH) was used to quantify the area of mineralized nodules.
2.12. Real time RT-PCR analysis
MC3T3-E1 cells were seeded in 6-well plates at a density of
2 × 105 cells/well. After 2 days of culture, cells were treated with DRTF
(2.5, 12.5, 62.5 μg/ml) for 12 h (6 wells per group). Total RNA was ex-
tracted from the treated cells using the RNAprep pure Tissue Kit accord-
ing to themanufacturer's instruction. After the cells were washed twice
with PBS, the concentration and purity of the RNA were determined by
measuring the absorbance at 260 nm and 280 nm. The RNA samples
(1000 ng) was reverse transcribed into complementary DNA (cDNA)
using the PrimeScript™ RT reagent kit. The PCR ampliﬁcation was car-
ried out on LightCycler96 Thermal Cycler (Roche, USA) with speciﬁc
primers and SYBR Premix Ex Taq™. The cycling parameters were as fol-
lows: pre-denaturation at 95 °C for 30 s, followed by 45 cycles of 95 °C for
10 s, 57 °C, 58 °C or 60 °C for 15 s, and 72 °C for 10 s. Following the PCR
reaction, melting curve analysis was conducted to verify the speciﬁcity
and identity of the PCR product. Ct values for the samples were normal-
ized to that of GAPDH and the relative expression was calculated via the
2−ΔΔCtmethod (Chang et al., 2009; Lau et al., 2008). All reactionswere
carried out in triplicate. The primer sequences are given in Table 1.
2.13. Western blotting
MC3T3-E1 cells were treatedwith DRTF (12.5 μg/ml). After 24 h of in-
cubation, cellswerewashedwith PBS and lysed inRIPA lysis solution. The
cell lysateswere centrifuged at 10,000 RPM for 10min at 4 °C. The super-
natants were collected and the total protein content was quantiﬁed with
a BCA assay kit. Then, 15 μg of total protein from each sample was sepa-
rated by SDS-PAGE (10% gel) and transferred to PVDF membranes. After
incubation in blocking solution (5% non-fatmilk, 0.05% Tween-20 in TBS)
for 2 h at room temperature, the membrane was incubated with an ap-
propriate primary antibody against OPG, RANKL, ERα, ERβ and GAPDH
at 4 °C overnight. After three washes with TBS containing 0.05% Tween-
20 (TBST), the membranes were incubated with horseradish peroxidase
(HRP) conjugated secondary antibody for 2 h at room temperature. Next,
the immunoreaction signals were detected with the enhanced ECL
chemiluminescence reagent kit (Biodragon-immunotech, China) and ex-
posed onGel Doc™XR+System (Bio-Rad, USA). The relative protein in-
tensities were quantiﬁed using Quantity One 1-D analysis software
(Bio-Rad, USA) and GAPDH was used as internal control.
2.14. Statistical analysis
Data are presented as themean±standard deviation (SD). One-way
ANOVAs were used to compare data from all groups and Turkey's tests
were used as a post-test to compare pairs of groups with the SPSS
16.0 statistical software (SPSS Inc., Chicago, IL, USA). Differences
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Table 2
Effects of TL on biochemical parameters in serum and urine of rats.
Parameters Sham OVX E2 TFDF25 TFDF75 TFDF225
S-Ca (mmol/l) 1.77 ± 0.18 1.79 ± 0.12 1.91 ± 0.31 1.74 ± 0.12 1.71 ± 0.03 1.69 ± 0.09
S-P (mmol/l) 1.48 ± 0.27 1.74 ± 0.51 1.85 ± 0.26 1.68 ± 0.25 1.47 ± 0.12 1.64 ± 0.20
U-Ca/Cr (mmom/mmol) 0.22 ± 0.05 0.39 ± 0.03⁎⁎ 0.24 ± 0.05## 0.29 ± 0.04# 0.29 ± 0.38# 0.27 ± 0.04##
U-P/Cr (mmom/mmol) 2.63 ± 0.50 3.83 ± 0.40⁎⁎ 3.01 ± 0.43## 3.17 ± 0.44 3.07 ± 0.43# 2.97 ± 0.45##
U-DPD/Cr (nmom/mmol) 50.23 ± 8.05 80.42 ± 6.45⁎⁎ 55.18 ± 3.72## 68.18 ± 5.39⁎⁎ 62.23 ± 3.90⁎,# 60.08 ± 6.95⁎,#
Trap (U/l) 3.07 ± 0.45 5.31 ± 0.75⁎⁎ 3.41 ± 0.74## 4.00 ± 0.62# 3.98 ± 0.42# 3.63 ± 0.81##
CTX-I (ng/ml) 2.89 ± 0.25 4.89 ± 0.43⁎⁎ 3.35 ± 0.39## 4.17 ± 0.51 3.63 ± 0.49## 3.28 ± 0.59##
OC (ng/ml) 2.24 ± 0.08 3.26 ± 0.29⁎⁎ 2.41 ± 0.41## 2.74 ± 0.25# 2.62 ± 0.15## 2.55 ± 0.24##
ALP (U/100 ml) 1.20 ± 0.38 2.34 ± 0.72⁎⁎ 1.36 ± 0.311## 1.74 ± 0.3 1.38 ± 0.37# 1.31 ± 0.22##
PICP (ng/ml) 2.49 ± 0.22 4.33 ± 0.56⁎⁎ 2.47 ± 0.41⁎⁎ 3.11 ± 0.49⁎ 2.93 ± 0.45⁎⁎ 2.63 ± 0.36⁎⁎
Note. Values are mean ± SD (n= 8).
⁎ p b 0.05 vs. Sham.
⁎⁎ p b 0.01 vs. Sham.
# p b 0.05 vs. OVX.
## p b 0.01 vs. OVX.
267S. Song et al. / Bone Reports 5 (2016) 262–273between means were considered statistically signiﬁcant when p-
values b 0.05.
3. Results
3.1. Quality assessment of DRTF extract
Naringin (Fig. 1A) and neoeriocitrion (Fig. 1B), which are two ﬂavo-
noids, were the main ingredients observed in the Drynariae Rhizoma.
Naringin is a commonly used marker for authentication of Drynariae
Rhizoma extract, according to the Chinese pharmacopoeia (China,
2015). In our research, naringin and neoeriocitrion were identiﬁed by
standard substance and mass spectrometry analysis. Fig. 1C is the
typical chromatography proﬁle of the two standards in which
neoeriocitrion showed a high peak at retention time 12.54 min and
naringin showed a high peak at retention time 20.41 min. A typical
HPLC chromatogram proﬁle of the DRTF is shown in Fig. 1D. The chem-
ical formula of naringin is C27H32O14 and its molecular weight is 580.54.
The chemical formula of neoeriocitrion is C27H32O15 and its molecular
weight is 596.174. Therefore, the ESI-MS m/z for naringin is 579 [M-
H]− and the ESI-MS m/z for neoeriocitrion is 595 [M-H]−. The primary
mass spectrograms of naringin and neoeriocitrion are shown in Fig. 1E
and F. Based on the normalization areas of the total chromatograms,
the relative percentage of naringin and neoeriocitrin in the DRTF were
32.92% and 43.43%, respectively.
3.2. Body and organ weights
The rats from six experimental groups had similar initial mean body
weights (p N 0.05). The body weights of all groups were increased under
the pair feeding conditions. The results showed that the growth rate of
the OVX group was higher than that of the Sham group (p b 0.01) on
week 4 after surgery, which also lasted throughout the experiment. E2
prevented increased body weight and returned the body weight near to
the level maintained by Sham group 4 weeks after treatment (p b 0.01).
DRTF (25 mg/kg/day) did not inﬂuence body weight, while DRTF (75
and 225 mg/kg/day) decreased the body weight to some degree
4 weeks later (Fig. 2A). Additionally, OVX caused signiﬁcant atrophy of
uterus compared with the Sham group (p b 0.001), indicating the success
of the surgical procedure. Administering E2 signiﬁcantly increased the
uterine weight compared with the OVX group (p b 0.001). On the con-
trary, none of the DRTF doses elicited the uterotropic effects of E2 (Fig.Fig. 2. Effects of DRTF or E2 on bodyweights and organ indices in OVX rats. (A) The bodyweigh
mean ± SD (n= 8), *p b 0.05, **p b 0.01compared with sham; #p b 0.05, ##p b 0.01 compared
determined as the uterus weight divided by body weight. Values are mean± SD (n= 8), *p b 0
dyed sections of rat uteri obtained from (a) Sham, (b) OVX, (c) E2, (d) DRTF25, (e) DRTF75, and
were isolated and weighed after the animals were sacriﬁced and the organ index was represen2B and C). The heart, liver, spleen, lung, kidney, brain and thymus organ
indices were not signiﬁcantly different among the groups (Fig. 2D).
3.3. Biochemical assay
The biochemical serum and urine parameters from all groups are
shown in Table 2 (Delmas et al., 2000). The OVX treatment did not alter
the S–Ca and S–P levels between all groups (p N 0.05 for all). Nevertheless,
the U–Ca and U–P levels in the OVX group were signiﬁcantly increased
compared with the Sham group (p b 0.01). Treatment with either DRTF
or E2 signiﬁcantly prevented the OVX-induced increase in U-Ca/Cr and
U-P/Cr levels (p b 0.05 or p b 0.01). Twelve weeks after OVX treatment,
bone resorption markers such as urinary DPD/Cr ratio, plasma TRAP
(Bonjour et al., 2012; de la Piedra et al., 1997), CTX-I, and bone formation
markers for plasma OC, ALP and PICP (Miura et al., 1995) were measured,
and all the tested parameters were signiﬁcantly increased in OVX group
(p b 0.01), However, the DRTF and E2 treatments prevented the OVX-in-
duced increase in the biochemical markers mentioned above (p b 0.05 or
p b 0.01). These results indicated that DRTF or E2 could prevent the OVX-
induced increase in the bone turnover rate in rats.
3.4. BMD and BMC evaluation
Therewere no differences in the right femur BMC values between all
of the treatment groups. However, The BMD was signiﬁcantly lower in
the OVX group compared with the Sham group (p b 0.001). The
twelve-week DRTF treatment at higher doses (75 or 225 mg/kg/day)
and the E2 treatment signiﬁcantly increased the right femur BMD levels
compared with the OVX group (p b 0.01) (Fig. 3).
3.5. Biomechanical quality test
A three-point bending test was performed to determine the effects
of DRTF on rat femur bone strength (Ederveen et al., 2001). As shown
in Table 3, after 12 weeks of estrogen deﬁciency, the max-load values
in OVX group reduced signiﬁcantly. The levels of energy and stiffness
in OVX group tended to decrease, however, they did not reach statistical
signiﬁcance compared with the Sham group. Although the E2 and DRTF
treatments altered the max-load, energy and stiffness levels, neither
E2 nor DRTF had signiﬁcant effects on the values of these three
biomechanical parameters compared with OVX group. However,
the OVX treatment signiﬁcantly reduced the max-stress and Young'sts of the animals were recorded every 2 weeks during the experimental period. Values are
with OVX. (B) Uteri were isolated and weighed after euthanization, the uterus index was
.001, ***p b 0.001 compared with sham; ^^^p b 0.001 compared with E2 treatment. (C) HE
(f) DRTF225 treated animals. (D) The heart, liver, spleen, lung, kidney, brain and thymus
ted as organ weight divided by body weight.
Table 3
Effects of 12-week DRTF treatment on biomechanical parameters in the femoral diaphysis of rats.
Parameters Sham OVX E2 TFDF25 TFDF75 TFDF225
Max-load [N] 129.68 ± 13.52 111.23 ± 3.53⁎ 124.19 ± 12.97 115.73 ± 5.99 118.60 ± 6.09 121.64 ± 8.59
Energy [N·mm] 102.09 ± 10.09 87.63 ± 5.35 97.40 ± 4.92 86.29 ± 6.19 88.12 ± 13.20 91.84 ± 6.52
Stiffness [N/mm] 209.08 ± 19.41 188.58 ± 10.95 204.02 ± 14.37 183.42 ± 17.31 198.32 ± 13.52 203.88 ± 12.94
Max-stress [MPa] 84.39 ± 6.49 67.01 ± 4.35⁎⁎ 81.05 ± 11.68# 71.21 ± 4.16 78.98 ± 5.80# 80.12 ± 4.76#
Young's modulus [MPa] 2244.41 ± 255.09 1703.88 ± 178.05⁎⁎ 2193.72 ± 222.64## 1976.55 ± 153.34 2088.63 ± 175.61# 2146.02 ± 291.95#
Note. Values are mean ± SD (n= 8).
⁎ p b 0.05, different from Sham.
⁎⁎ p b 0.01, different from Sham.
# p b 0.05, different from OVX.
## p b 0.01, different from OVX.
Fig. 3. Effects of 12-week treatmenton theBMDandBMC in the femurofOVXratsbyDEXA.Values aremean±SD(n=8), ***pb 0.001different fromSham;#pb 0.05, ##pb 0.01different fromOVX.
268 S. Song et al. / Bone Reports 5 (2016) 262–273modulus (p b 0.01). Compared with the OVX group, treatment
with E2 or DRTF (75 or 225 mg/kg/day) signiﬁcantly prevented the
decreases in max-stress and Young's modulus in the OVX rats
(p b 0.05 or p b 0.01).
3.6. Micro CT evaluation
Three-dimensional images of femoral metaphysis showed differ-
ences in trabecular microarchitecture amongst the various treatmentFig. 4. Representative sample from each group: 3D architecture of trabecular bone within the
DRTF225.groups, as represented in Fig. 4A–F. Analysis of the representative sam-
ples indicated that OVX signiﬁcantly decreased the trabecular BV/TV,
Tb.N, and Tb.Th levels (p b 0.001) compared with the Sham group. In
contrast, the distal femur Tb.Sp and Tb.Pf levels in the OVX rats were
signiﬁcantly increased compared with the Sham group (p b 0.01). Com-
pared with the OVX group, the DRTF (75 or 225mg/kg/day) or E2 treat-
ments reversed the effectsmentioned above at somedegree amongst all
of the groups. Nevertheless, the thickness of cortical bone had no signif-
icant difference in each group (Table 4).distal metaphyseal femur region: (A) Sham, (B) OVX, (C) E2, (D) DRTF25, (E) DRTF75, (F)
Table 4
Micro CT 3D parameters of trabecular bone in the distal femur region.
Parameters Sham OVX E2 DRTF25 DRTF75 DRTF225
BV/TV (%) 0.54 ± 0.04 0.31 ± 0.06⁎⁎⁎ 0.45 ± 0.04## 0.35 ± 0.04⁎⁎ 0.42 ± 0.04# 0.42 ± 0.02#
Tb.Th (mm) 0.12 ± 0.02 0.08 ± 0.01⁎⁎⁎ 0.12 ± 0.01## 0.10 ± 0.01 0.11 ± 0.01# 0.11 ± 0.01#
Tb.N (1/mm) 5.12 ± 0.14 2.89 ± 0.11⁎⁎⁎ 4.66 ± 0.50### 3.79 ± 0.13 4.33 ± 0.29⁎⁎ 4.49 ± 0.46##
Tb.Sp (mm) 0.02 ± 0.01 0.19 ± 0.05⁎⁎ 0.10 ± 0.02# 0.16 ± 0.02 0.11 ± 0.04# 0.10 ± 0.02#
Tb.Pf (1/mm) 4.66 ± 0.65 8.32 ± 1.00⁎⁎ 5.06 ± 0.84# 6.67 ± 0.75 5.41 ± 0.80# 5.04 ± 0.39#
Ct.Th (mm) 0.48 ± 0.002 0.45 ± 0.02 0.46 ± 0.02 0.45 ± 0.02 0.46 ± 0.01 0.46 ± 0.03
Note. Values are mean ± SD (n= 8).
⁎⁎ p b 0.01, different from Sham.
⁎⁎⁎ p b 0.001, different from Sham.
# p b 0.05, different from OVX.
## p b 0.01, different from OVX.
### p b 0.001, different from OVX.
269S. Song et al. / Bone Reports 5 (2016) 262–2733.7. Effects of DRTF on the differentiation of MC3T3-E1 cells
The cell proliferation rates, asmeasured by theMTT assay,were signif-
icantly increasedwhen the cells were treated with DRTF (12.5 or 62.5 μg/
ml) (p b 0.01 for all) (Fig. 5). Based on this preliminary observation, we
evaluated the differentiation-inducing activities of DRTF on MC3T3-E1
cells by assessing ALP activity. ALP activity is a phenotypic marker for
early differentiation of osteoblasts. When MC3T3-E1 cells were treated
with different concentrations (0.1, 0.5, 2.5, 12.5, 62.5, 312.5 μg/ml) of
DRTF for different time points, the ALP activity increased in a time-depen-
dent manner, with a maximum activity level observed on the 9th day;
however, it decreased on the 12th day. DRTF (12.5 or 62.5 μg/ml) exhib-
ited signiﬁcant stimulating effects on cell differentiation (p b 0.01 or
p b 0.05), while it decreased cell differentiation at 312.5 μg/ml. As the
strongest activity obtained by the above experiments was 12.5 or
62.5 μg/ml, this concentration was used in the following experiments.Fig. 5. Effects of DRTF on the proliferation and differentiation of MC3T3-E1 cells: (A) Cell proli
**p b 0.01 vs. control. (B) ALP activity was assessed using Alkaline Phosphate Assay Kit. Values
Fig. 6.Mineralized nodules formation ofMC3T3-E1 cells culturedwith osteogenicmedium. (A)
(b) DRTF (12.5 μg/ml) treatment, bar: 100 μm. (B) Quantitative analysis of the area of minerali3.8. Effects of DRTF on MC3T3-E1 cell maturation
The formation ofmineralized nodules is one of the importantmarkers
during osteoblastic maturation. MC3T3-E1 cells were incubated with
DRTF (12.5 μg/ml) in osteogenic medium for 12 days and stained with
Alizarin Red S to detect mineralized nodule formation, as represented
by bright red color. The mineralized areas in MC3T3-E1 cells cultured
with DRTF showed remarkably increased intensity compared with the
control (Fig. 6). In addition to the obvious color change, the amount of
mineralized nodules following DRTF treatment was signiﬁcantly higher
than that of the control (p b 0.01).
3.9. Effects of DRTF on OPG and RANKL expression
Osteoprotegrin (OPG) and receptor activator of NF–κB ligand
(RANKL) were identiﬁed as the dominant and ﬁnal mediators offeration of MC3T3-E1 was evaluated by the MTT method. Values are mean ± SD (n= 8),
are mean ± SD (n= 8), *p b 0.05, **p b 0.01 vs. control.
Representative images ofmineralized nodules stained by Alizarin Red S, (a) DMEMcontrol,
zed nodules using Image J software. Values are mean ± SD (n= 3), **p b 0.01 vs. control.
Fig. 7. Effects of DRTF on OPG and RANKLmRNA expression in MC3T3-E1 cells. MC3T3-E1 cells were treated with vehicle (control), E2 and different concentrations of DRTF (2.5, 12.5 and
62.5 μg/ml) for 12 h. Total RNAwas isolated and real-time RT-PCRwas performed to determine themRNA expression levels of OPG (A) and RANKL (B), which were normalized to that of
GAPDH. The results are expressed as themean±SD (n=3). (C) Effect of DRTF on theOPG/RANKLmessage level ratio inMC3T3-E1 cells. Data are presented as themean ratio ofOPG:RANKL
expression ± SD (n= 3). *p b 0.05, **p b 0.01 vs. control.
270 S. Song et al. / Bone Reports 5 (2016) 262–273osteoclastogenesis (Bord et al., 2003; Zhang et al., 2014b). As shown in
Fig. 7A, DRTF at 12.5 and 62.5 μg/ml signiﬁcantly increased OPG expres-
sion inMC3T3-E1 cells (p b 0.01 or p b 0.05). On the contrary, RANKL ex-
pression was down-regulated following DRTF treatment (p b 0.01) (Fig.
7B). The OPG to RANKL ratio was then calculated to demonstrate its ef-
fects on osteoclastogenesis. The results showed that the ratiowas signif-
icantly increased in the DRTF group (12.5 and 62.5 μg/ml) compared
with the control (p b 0.01 or p b 0.05) (Fig. 7C).
We then detected the protein production of OPG and RANKL in the
presence and absence of DRTF (12.5 μg/ml) using western blotting
(Fig. 8). The results were consistent with the gene expression levels,
which indicated that DRTF can inhibit osteoclastogenesis by decreasing
the direct interaction between RANKL expression on osteoblasts and
RANK expression on the osteoclast cell surface.
3.10. Effects of DRTF on ERα and ERβ expression
To determine whether DRTF could alter ER expression, the ERα and
ERβ expression levels were studied. Our results indicated that E2
(10−11 M) activated ER-dependent transcription activity via ERα
(p b 0.01 vs. control) as well as ERβ (p b 0.001 vs. control). Additionally,
DRTF increased the ERα and ERβ expression levels in a concentration
dependent manner. DRTF at concentration of 12.5 and 62.5 μg/mlFig. 8. Effects of DRTF on the OPG and RANKL protein levels inMC3T3-E1 cells. (A)Western blo
(12.5 μm/ml) for 48 h. (B) “Quantity one” from Bio-Rad was used to analyze the western blotsigniﬁcantly enhanced ERα and ERβ expression in the MC3T3-E1 cells
(Fig. 9A, B, p b 0.05 or p b 0.01 vs. control).
Moreover, we examined the protein production of ERα and ERβ in
the presence or absence of DRTF using western blotting. As shown in
Fig. 10A, E2 and DRTF (62.5 μg/ml) signiﬁcantly up-regulated ERα and
ERβ expression in the MC3T3-E1 cells (Fig. 10B, p b 0.05 or p b 0.01 vs.
control).
4. Discussion
Drynariae Rhizoma and other kidney-tonifying traditional Chinese
medicines have been widely used for thousands of years to treat frac-
tures and joint diseases. In the present study, we evaluated the skeletal
effects of DRTF on osteoporotic rats and explored the possible osteogen-
ic effect mechanisms.
In order to evaluate the positive DRTF-mediated effects for the treat-
ment of PMOP, the internationally accepted OVX rat model was utilized
in this study (Nakamuta, 2004). As expected, OVX resulted in a signiﬁ-
cant reduction in the total BMD in the femur after 12 weeks. This loss
in bone mass was accompanied by a signiﬁcant simultaneous increase
in bone remodeling, as was demonstrated by the enhanced bone turn-
over marker levels, such as Ca/Cr, P/Cr, DPD/Cr, CTX-Ι, PICP, OC, ALP
and Trap. These results suggested that OVX alters calcium metabolismt analysis of OPG and RANKL expression after treatment of MC3T3-E1 cells with E2 or DRTF
results, the values represent mean ± SD (n= 3), *p b 0.05, **p b 0.01 vs. control.
Fig. 9. Effects of DRTF on ERα and ERβmRNA expression in MC3T3-E1 cells. MC3T3-E1 cells were treated with vehicle (control), E2 and different concentrations of DRTF (2.5, 12.5 and
62.5 μg/ml) for 12 h. Total RNA was isolated and real-time RT-PCR was performed to determine the mRNA expressions levers of ERα (A) and ERβ (B), which were normalized to that
of GAPDH. The results were expressed as the mean ± SD (n= 3), *p b 0.05, **p b 0.01 vs. control.
271S. Song et al. / Bone Reports 5 (2016) 262–273and causes a signiﬁcant increase in bone turnover rate. Treatment with
DRTF or E2 prevented the decreased total BMD levels, which were
reﬂected by the decreased bone turnover markers mentioned above.
In summary, these results indicate a reduction in the bone turnover
rate after treatment with DRTF and E2.
Although such inhibition would generally be considered beneﬁcial,
biomechanical bone competence may be compromised if bone remod-
eling is excessively inhibited (Ederveen et al., 2001). Therefore, the
three-point bending test was carried out to investigate the effects of
DRTF on the biomechanical properties of the femurs from the OVX
rats. Structural biomechanical properties (i.e., maximum load, stiffness
and energy) are inﬂuenced by bone material properties and by the
bone architecture or geometric properties, which are called extrinsic
biomechanical properties. The actual effect from the treatment with re-
gard to biomechanical competence can only be fully evaluated bymate-
rial biomechanical parameters such as maximum stress and Young's
modulus, which are called intrinsic biomechanical properties (Turner
and Burr, 1993). From a biomechanical point of view, an ideal drug for
bone fragility treatment should improve bone strength and decrease
brittleness, in order to improve the extrinsic biomechanical properties
of the bone but not substantially impair its intrinsic properties (Zhang
et al., 2014a). In fact, it is very difﬁcult to achieve this combination ofFig. 10. Effects of DRTF on the ERα and ERβ protein level in MC3T3-E1 cells. (A) Western blot
(62.5 μm/ml) for 48 h. (B) “Quantity one” from Bio-Radwas used to analyze thewestern blottineffects. Fluoride treatment is a good example, as ﬂuoride can improve
bone mass (Haguenauer et al., 2000); however, ﬂuoride incorporation
into bone mineral reduces its intrinsic biomechanical properties
(Turner et al., 1995). Our data conﬁrmed that it is difﬁcult to simulta-
neously improve the intrinsic and extrinsic properties. After 12 weeks
of daily treatment, the DRTF or E2 treatments only promoted the intrin-
sic properties of the femur. The improvement in the intrinsic properties
may be due to the trabecular bone structure optimization.
Preservation of the trabecular bone architecture signiﬁcantly
promotes bone strength and may be more important in decreasing
fracture risk than improving BMD (Bouxsein, 2003). Therefore,
microarchitecture determinants are necessary to evaluate the true im-
pact of a treatment on trabecular bone quality (Marinozzi et al., 2013;
Muller et al., 2004;Wronski et al., 1989). The results of the micro CT in-
dicated that the morphometric parameters (BV/TV, Tb.Th and Tb.N) of
the trabecular bone at the distal femur were improved in the OVX rats
in response to 12weeks of daily oral treatmentwith DRTF. Furthermore,
the DRTF treatment decreased the ovariectomy-induced alterations of
the Tb.Sp and Tf.Pf, indicating that the deterioration of the microstruc-
tural geometry of the trabecular bone was largely prevented. Although
we observed some positive effects from theDRTF treatments on the tra-
becular bone micro-architectural properties, none of the treatments,analysis of ERα and ERβ expressions after treatment of MC3T3-E1 cells with E2 or DRTF
g results. The values were expressed asmean± SD (n=3), *p b 0.05, **p b 0.01 vs. control.
272 S. Song et al. / Bone Reports 5 (2016) 262–273including E2, were able to restore the deteriorated trabecular bone
(Devareddy et al., 2006). These ﬁndings are consistent with those of
other studies in which the trabecular structure restoration were unable
to be observed after its deterioration had occurred, emphasizing the
need for trabecular bone loss prevention (Laib et al., 2001).
The in vitro study usingMC3T3-E1 cells provided further support for
the potential action of DRTF on bone. DRTF not only promoted prolifer-
ation and increased ALP activity but it also enhanced the formation of
mineralized nodules in osteoblasts. These results indicated that DRTF
might participate in multiple stages of the osteoblast differentiation
process, from early to terminal stages, to stimulate osteoblast cell differ-
entiation andmaturation.We also determined the expression of several
important proteins that are involved in the osteoblast differentiation
process as well as osteoclastogenesis in bone, such as OPG, RANKL,
ERα and ERβ. With the recent discovery of RANKL–RANK interaction,
the role of osteoblasts in osteoclast differentiation is now clearly de-
ﬁned. Binding of RANKL secreted from osteoblastic cells to RANK on
the osteoclast cell surface results in an induction of osteoclast function,
whereas, the secretion of OPG (the soluble decoy receptor of RANKL) by
osteoblasts can interferewith RANKL–RANK interactions,which inhibits
osteoclastogenesis (Boyce and Xing, 2008; Theoleyre et al., 2004). The
present study showed that DRTF (12.5 μg/ml) stimulated OPG and sup-
pressed RANKL expression, leading to an increased expression ratio of
OPG/RANKL in ME3T3-E1 cells, which might inhibit osteoclastogenesis
via modulation of the OPG/RANKL system in osteoblastic cells. Further-
more, previous studies reported that DRTF can up-regulate bone-related
gene expression that are involved in bone formation (such as Smad1
and Smad5) (Zhu et al., 2010), suppress the circulatory level of cyto-
kines involved in inducing bone resorption (TNF-α and IL-6), and stim-
ulate cytokines (i.e., IL-4) associated with bone resorption suppression
in OVX rats (Xie et al., 2004; Zhu et al., 2010).
Estrogen is one of themost important hormones in thebody. It is pri-
marily secreted by the ovaries, testicle and hypothalamus and plays a
physiological role by binding two ER subtypes (ERα and ERβ). ERβ is
more abundant in bone tissue while ERα is mainly distributed in repro-
ductive cells, especially those of the breast and uterus. A previous study
showed that the presence of ERβ-like immunoreactivity in the nuclei of
human and murine osteoblasts and osteocytes and in the cytoplasm of
osteoclasts and chondrocytes (Kuiper et al., 1998). Supplemental estro-
gen can inhibit osteoclast activity and reduce high bone turnover rate.
Additionally, long-term supplement can increase estrogen levels,
resulting in hyperplasia of the endometrium and ductal epithelial
cells, which can increase the risk of breast and uterine cancer
(Hvidtfeldt et al., 2015). Although the osteo-protective effects of DRTF
in vivo were similar to those of E2 as reported in studies by others
(Magnusson and Weiderpass, 2001; Morch et al., 2012; Morch et al.,
2009), DRTF did notmimic the effects of E2 on uterus weight. Moreover,
DRTF is also safe for the body, as the organ indexeswere not signiﬁcant-
ly different amongst the groups. The in vitro study showed that DRTF
(62.6 μg/ml) improved both ERα and ERβ expression levels in the
MC3T3-E1 cells. The results demonstrated that DRTF behaves as a phy-
toestrogen and exerts positive effects in bone cells via ER-dependent
pathways. Themechanism of the action of the phytoestrogens is similar
to the estrogen, which then combines with the estrogen receptor, acts
on the estrogen response element in the nucleus, and exerts its physio-
logical function (Boonchird et al., 2010).
In conclusion, DRTF administrationwas able to prevent estrogen de-
ﬁciency induced bone mass decrease and deterioration of trabecular
microarchitecture without hyperplastic effects on the uterus and other
organs, thus maintaining the structural integrity and biomechanical
qualities of the bone. Moreover, DRTF appeared to exert positive effects
on bone formation, while negativelymodulating bone resorption. These
effects seem to be related to the high content of ﬂavonoids that behave
as phytoestrogens but did not act the same as estrogen. Our study may
provide evidence to support the use of DRTF as a reasonable alternative
for the prevention and treatment of PMOP.5. Conclusions
In this study, we systematically evaluated the protective effects of
DRTF on OVX-induced bone loss in female rats and explored the possi-
ble mechanism of their therapeutic effects. The data demonstrated
that DRTF could prevent OVX-induced bone loss without uterine estro-
genic effects. Such a bone-protective role makes it a promising alterna-
tive agent for the safe and effective treatment of PMOP. As the major
active ingredients in DRTF are naringin and neoeriocitrin, evaluation
of their effects in an ovariectomized rat model is in process.
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